Articles related to TARGETED THERAPIES

Data from Study 2102-HEM-101, an open-label, single-arm, multicenter phase 1/2 trial, were used to support the approval. The Abbott RealTime IDH1 Assay was used to identify 147 adults with relapsed or refractory AML who had an IHD1 mutation. Olutasidenib treatment resulted in a 35% complete remission (CR) or complete remission with partial hematologic recovery in patients (CRh).

Amar Gajjar, MD, who serves as the co-chair of the oncology department and chair of the pediatric medicine department at St. Jude Children’s Research Hospital in Memphis, Tennessee, answers questions from our friends at Cancer Therapy Advisor. Proton therapy, conventional chemotherapy, targeted therapies, and observed glioma progression are all topics covered by Dr. Gajjar when talking about treatment options for pediatric low-grade gliomas (pLGG) that have relapsed or progressed.

A Q&A with John N. Allan, MD, Assistant Professor of Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine in New York, who discusses the changing role of prognostic markers, the usefulness of the markers, the biomarkers that should be part of standard testing, when patients should be tested, and much more.

As yet, there are no consensus treatment strategies for class 2 and 3 BRAF mutations. This systematic review and meta-analysis of published reports of patients with class 2 or 3 BRAF mutations from 2010 to 2021 assesses MAPK targeted therapy in the setting. The meta-analysis suggests that MAPK TTs have clinical activity in some class 2 and 3 BRAF-mutant cancers.

This paring of PARP inhibitor and immune checkpoint inhibitor may be a viable non-cytotoxic maintenance therapy option for patients with platinum-sensitive pancreatic ductal adenocarcinoma. At a median follow-up of 23.0 months, combining the PARP inhibitor niraparib with the anti CTLA-4 antibody ipilimumab achieved a 6-month PFS rate of 59.6%, which was superior to the comparator — a clinically meaningful benchmark of 44%. The results were not the same when a PD-1 inhibitor (nivolumab) were used. That trial arm yielded a poorer 6-month PFS vs the benchmark.

Guideline-directed binary distinctions between HER2-positive and HER2-negative breast cancer have guided physicians’ treatment decisions for quite some time, but new research suggests that patients with HER2-2+, ISH-negative breast cancer present a clinical picture closer to that of patients with HER2-positive breast cancer, offering up a new nomenclature, HER2-low.